Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease
- PMID: 28555525
- DOI: 10.1080/08923973.2017.1327965
Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease
Erratum in
-
Correction to: Bahabadi M, et al., Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease.Immunopharmacol Immunotoxicol. 2017 Oct;39(5):x. doi: 10.1080/08923973.2017.1352255. Epub 2017 Jul 10. Immunopharmacol Immunotoxicol. 2017. PMID: 28691883 No abstract available.
Abstract
Context: The active ingredients of traditional medical herbs have been the focus of scientific interests.
Objective: This study was designed to explore the mechanisms of actions of parthenolide on nonalcoholic fatty liver disease (NAFLD).
Materials and methods: Thirty-five male Wistar rats were fed high-fat diet (HFD) for eight weeks with or without an intraperitoneal injection of parthenolide to develop NAFLD. Liver triacylglycerol (TG), total antioxidant capacity (TAC), total oxidative status (TOS), thiobarbituric acid reactant substances (TBARs), total thiol groups and tumor necrosis factor alpha (TNF-α) and cytochrome P4502E1 (CYP2E1) levels as well as liver ALT, AST and catalase activities were determined. In addition, quantitative real-time PCR was performed to obtain hepatic gene expression levels of TNF-α, CYP2E1 and nuclear factor-κB (NF-κB).
Results: HFD caused a significant weight gain and increased liver TG content as well as alteration in ALT and AST activities, which were attenuated after administration of parthenoide (p < .05). Weakened liver antioxidant system (TAC, total thiol groups and catalase activity) and increased oxidative stress markers (TBARs and TOS) were mainly ameliorated by parthenolide treatment (p < .05). Increased hepatic TNF-α, NF-κB and CYP2E1 at the both gene expression and protein levels were found associated with necroinflammatory changes in histopathological observations and were abrogated almost completely after parthenolide treatment. Oxidative and inflammatory changes observed in HFD fed rats were indicative of NAFLD, which were suppressed with parthenolide treatment.
Conclusions: Based on these results, parthenolide might be a candidate agent for preventing NAFLD due to its anti-inflammatory and anti-oxidative potency.
Keywords: Cytochrome P450 CYP2E1; NF-kappa B; high-fat diet; non-alcoholic fatty liver disease; parthenolide; tumor necrosis factor-alpha.
Similar articles
-
Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.World J Gastroenterol. 2016 Dec 14;22(46):10180-10188. doi: 10.3748/wjg.v22.i46.10180. World J Gastroenterol. 2016. PMID: 28028366 Free PMC article.
-
Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.Eur J Pharmacol. 2015 Feb 5;748:123-32. doi: 10.1016/j.ejphar.2014.12.017. Epub 2014 Dec 24. Eur J Pharmacol. 2015. PMID: 25542756
-
Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.J Oleo Sci. 2019 Jun 6;68(6):581-589. doi: 10.5650/jos.ess19018. Epub 2019 May 16. J Oleo Sci. 2019. PMID: 31092797
-
Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway.Clin Investig Arterioscler. 2021 Sep-Oct;33(5):257-266. doi: 10.1016/j.arteri.2020.12.007. Epub 2021 Mar 31. Clin Investig Arterioscler. 2021. PMID: 33810882 Review. English, Spanish.
-
New insight and potential therapy for NAFLD: CYP2E1 and flavonoids.Biomed Pharmacother. 2021 May;137:111326. doi: 10.1016/j.biopha.2021.111326. Epub 2021 Feb 5. Biomed Pharmacother. 2021. PMID: 33556870 Review.
Cited by
-
NLRP3: a new therapeutic target in alcoholic liver disease.Front Immunol. 2023 Jul 13;14:1215333. doi: 10.3389/fimmu.2023.1215333. eCollection 2023. Front Immunol. 2023. PMID: 37520548 Free PMC article. Review.
-
Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway.Mol Med Rep. 2021 Jul;24(1):487. doi: 10.3892/mmr.2021.12126. Epub 2021 May 6. Mol Med Rep. 2021. PMID: 33955510 Free PMC article.
-
Hepatoprotective Effects of Silymarin on Liver Injury via Irisin Upregulation and Oxidative Stress Reduction in Rats with Type 2 Diabetes.Iran J Med Sci. 2019 Mar;44(2):108-117. Iran J Med Sci. 2019. PMID: 30936597 Free PMC article.
-
Deacetylation via SIRT2 prevents keratin-mutation-associated injury and keratin aggregation.JCI Insight. 2023 Jul 24;8(14):e166314. doi: 10.1172/jci.insight.166314. JCI Insight. 2023. PMID: 37485877 Free PMC article.
-
The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.Front Pharmacol. 2022 Mar 8;13:780496. doi: 10.3389/fphar.2022.780496. eCollection 2022. Front Pharmacol. 2022. PMID: 35350750 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous